<p><strong>Pediatric Use</strong>: Safety and effectiveness of Tenofovir Alafenamide in pediatric patients less than 18 years of age have not been established.<br />
<br />
<strong>Geriatric Use</strong>: Clinical trials of Tenofovir Alafenamide did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects.<br />
<br />
<strong>Renal Impairment</strong>: No dosage adjustment of Tenofovir Alafenamide is required in patients with mild, moderate, or severe renal impairment. Tenofovir Alafenamide is not recommended in patients with end stage renal disease (estimated creatinine clearance below 15 mL per minute)&nbsp;<br />
<br />
<strong>Hepatic Impairment</strong>: No dosage adjustment of Tenofovir Alafenamide is required in patients with mild hepatic impairment (Child-Pugh A). The safety and efficacy of Tenofovir Alafenamide in patients with decompensated cirrhosis (Child-Pugh B or C) have not been established; therefore Tenofovir Alafenamide is not recommended in patients with decompensated (Child-Pugh B or C) hepatic impairment</p>